Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. - Wikidata - awgldk - TriplyDB

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

http://www.wikidata.org/entity/Q46184588

about

Anti-Apoptotic Effects of Lentiviral Vector Transduction Promote Increased Rituximab Tolerance in Cancerous B-Cells Isoflurane preconditioning increases B-cell lymphoma-2 expression and reduces cytochrome c release from the mitochondria in the ischemic penumbra of rat brain.Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.Lyn regulates inflammatory responses in Klebsiella pneumoniae infection via the p38/NF-κB pathway.Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies.Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.Empowering targeted therapy: lessons from rituximab.Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis.Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer Can we develop biomarkers that predict response of cancer patients to immunotherapy?Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma Rituximab therapy in malignant lymphoma.Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells.MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.Anti-CD20 monoclonal antibodies: historical and future perspectives.Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.Cell type-specific regulation of IL-10 expression in inflammation and disease.Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals.Mechanisms of action of CD20 antibodies.p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.RNA-binding protein AUF1 regulates lipopolysaccharide-induced IL10 expression by activating IkappaB kinase complex in monocytes.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway.Quercetin potentiates the antitumor activity of rituximab in diffuse large B-cell lymphoma by inhibiting STAT3 pathway.Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells.Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.Heat stress upregulates chaperone heat shock protein 70 and antioxidant manganese superoxide dismutase through reactive oxygen species (ROS), p38MAPK, and Akt.

P2860

Q28551184-F233ADE4-168C-485A-9654-2667F939272E Q30439574-043A9586-20CC-4B27-A790-79DA2714F0D3 Q33919290-07CBDECB-BD61-4281-841D-E5597E09285E Q33922067-59C9B25F-D1B5-465D-ABF3-7A40CDBA3BA0 Q34255098-54F4F5A5-DB75-4EB2-93FD-A73876470868 Q34369841-791026A5-FDC0-4AAA-AAF4-1C196CA38129 Q34480157-C4FFDEB3-1C89-463A-98AF-6B3616EFCE4F Q34700655-28ADE630-288F-4DBB-B3C8-EFE169F8E71E Q35562656-ABF89BCD-E7E4-4A7A-9CA5-3864611C7CAA Q35760627-CC265D18-E4EF-4DB2-A74B-FC84503E9FDB Q35811165-C0D011AC-535F-4077-B967-14B91D17A6F9 Q35835795-3E34EE9C-E7E5-4051-84C2-69065CFE86B5 Q35911103-C3109F84-7899-48E1-A107-4C4FC29CAAAE Q36042724-714B2DE8-2A49-4CCF-A1F9-2282C72151E3 Q36318014-F0E3CB73-0DBB-4C46-A91F-59B8295A4B6E Q36429463-BA93FD72-B348-436F-AC3A-01DB8CA96FBC Q36528137-85A0A70E-50DE-400B-9929-52850C2084ED Q36575331-B7D8924B-FBAA-4488-82B5-11A4ED2394F4 Q36609581-CC9E939A-4D23-4874-88EB-84E85E5A8960 Q36832102-E66BAE34-232A-4FC6-BD24-E953A57B30A4 Q36832106-A8D675B3-D7AF-46B0-8416-13B864CC4E61 Q36836856-3B7917BE-F89A-4817-8569-AD2D1207937E Q37044582-4214586A-A95C-42F8-A9A1-A2E07F16DCEE Q37210723-303BF37C-A90A-4AAD-A4C9-B2B408714E19 Q37448352-28FC1EAA-7E2B-4999-8FF8-4B3086C30696 Q37601775-F1A2C9EA-E0A0-4336-AF84-5EAD43DD43A0 Q37613872-FCD8034E-C8C6-4852-9BE8-FADB24D3FADB Q37678256-C40636FA-2E11-43AC-A85B-2D5D8B5ADA81 Q37699251-702A29F9-9078-460B-9853-0C5BB33D35A7 Q38046653-7384661C-FA9D-4299-95AE-26251753BBA7 Q38066195-54E23D09-8792-4C53-82C5-A7FF59B1DF5E Q38128304-A12EBCD5-8EAC-49A4-9F41-DF393B37C632 Q38273851-07970D31-5033-41FB-BEC8-E3B2A9A138AB Q38338870-E7825472-A597-43B0-8251-CAE579E88519 Q38824182-120DC143-C254-49C4-A299-F7F069ECEDAB Q38921915-7562A1D4-9B5A-437C-AFD9-640A29D14A6A Q38987923-27DA3EAD-2415-48FE-A142-D23415D315D4 Q39305171-C80E7240-2CAB-48BD-B801-49404C318081 Q39493955-4C936F84-38E5-4D6A-8BE3-5D07679B10C5 Q39871976-C7B1A74F-5298-4B17-999A-056F12EB2C14

P2860

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

http://www.wikidata.org/entity/Q46184588

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Rituximab inhibits p38 MAPK ac ...... f p38 MAPK in drug resistance.

@en

Rituximab inhibits p38 MAPK ac ...... f p38 MAPK in drug resistance.

@nl

type

label

Rituximab inhibits p38 MAPK ac ...... f p38 MAPK in drug resistance.

@en

Rituximab inhibits p38 MAPK ac ...... f p38 MAPK in drug resistance.

@nl

prefLabel

Rituximab inhibits p38 MAPK ac ...... f p38 MAPK in drug resistance.

@en

Rituximab inhibits p38 MAPK ac ...... f p38 MAPK in drug resistance.

@nl

P1433

Q46184588-25508634-AB49-4F15-9402-FD3F58CE2DF0

P1476

Q46184588-27C94FA6-F12B-4FBB-98D8-0A7E56FA3605

P2093

Q46184588-1719CC06-8D6D-440C-A5D2-2E85E9EC4344

Q46184588-94BC4B72-D3B2-4A9B-BDB0-6A85E625E243

Q46184588-9DC397F1-5A74-485E-A365-9457B64126CC

Q46184588-A3ECF32B-B752-4CD5-9C75-DE69B8454667

P2860

Q46184588-12B20037-DAC3-48AD-B494-4F0AF2D2C5E1

Q46184588-2B7FCFA9-078E-412E-BE8A-ACBFA98231E9

Q46184588-74ACF91B-0A93-42FE-ABEE-638EB4C4B69A

Q46184588-A25235F8-86AF-468F-882E-216C46E239E1

Q46184588-B1AAE6E7-DA2B-4810-A262-DFA88CD7AA7F

Q46184588-BFCF68C8-8262-4C47-A1B8-0CF9BEF24985

Q46184588-CB5360E9-006A-476C-8F92-32C73141F972

Q46184588-DC39717F-9321-47F1-940C-E4CD73B06258

Q46184588-F703D2FB-42BC-4725-9802-2DB91FC9EFC0

P2888

Q46184588-9C9B4044-BCD5-4868-B17F-E6CBE8DC1FD4

P304

Q46184588-FDDBA7B9-0802-48B8-933B-7B9B45437C74

P31

Q46184588-B56A1FBA-3564-48E9-82A4-F5F6CD616EDD

P356

Q46184588-A33AB401-50D3-46A1-8659-310EF2EC4334

P407

Q46184588-8CCE7BBB-2711-4132-A93A-E4B0E06D3144

P433

Q46184588-96322BF4-4469-4A11-9FFA-D0357D8FFB7D

P478

Q46184588-17846FF4-A631-4324-9EEA-3C8A230FD943

P50

Q46184588-0B63992B-280E-4072-BF41-A1977841FB76

Q46184588-549E5009-C993-461D-A540-5DB3B8090014

P577

Q46184588-1BE37314-5073-4442-8994-7DC5F1D68401

P5875

Q46184588-5EB45031-56A1-4F44-8E19-FA560644CDB6

P698

Q46184588-DEA3562D-8032-48D7-9CC6-9B8320256E3B

P356

P1433

P1476

Rituximab inhibits p38 MAPK ac ...... of p38 MAPK in drug resistance

@en

P2093

Ali Jazirehi

http://www.w3.org/2001/XMLSchema#string

Benjamin Bonavida

http://www.w3.org/2001/XMLSchema#string

Christos Emmanouilides

http://www.w3.org/2001/XMLSchema#string

Sara Huerta-Yepaz

http://www.w3.org/2001/XMLSchema#string

P2860

Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

MAP kinases in the immune response.

Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence.

Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway

Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.

The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages.

A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages.

Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells.

P2888

P304

3530-3540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1207336

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8625549

http://www.w3.org/2001/XMLSchema#string

P698

15077178

http://www.w3.org/2001/XMLSchema#string